Skip to content
Peptigraph home

Retatrutide Phase 2 trial (NCT04867785)

A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
281
actual
Start
13 May 2021 (actual)
Primary completion
8 Jul 2022 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT04867785 study arms
ArmTypeInterventionsDescription
0.5 milligrams (mg) LY3437943ExperimentalDrug: LY3437943Participants received 0.5 mg LY3437943 administered as SC (subcutaneous) injection once weekly (QW).
4 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.
4 mg LY3437943 (4 mg)ExperimentalDrug: LY3437943Participants received 4 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.
8 mg LY3437943 (4 mg)ExperimentalDrug: LY3437943Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as a SC injection QW.
12 mg LY3437943 (2 mg)ExperimentalDrug: LY3437943Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, then 8 mg LY3437943, then 12 mg LY3437943 administered as a SC injection QW.
1.5 mg DulaglutideActive comparatorDrug: DulaglutideParticipants received 1.5 mg dulaglutide administered as SC single-dose pen injection QW.
PlaceboPlacebo comparatorDrug: PlaceboParticipants received placebo administered as SC injection QW.
Endpoints

Primary endpoint

NCT04867785 primary outcomes
MeasureTime frame
Change From Baseline in Hemoglobin A1c (HbA1c)Baseline, 24 Weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04867785 secondary outcomes
MeasureTime frame
Change From Baseline in HbA1cBaseline, 24 Weeks
Change From Baseline in HbA1cBaseline, 36 Weeks
Percentage of Participants Reaching HbA1c <7.0%Week 24
Percentage of Participant Reaching HbA1c <7.0%Week 36
Change From Baseline in Fasting Blood Glucose (FBG)Baseline, 24 Weeks
Change From Baseline in Fasting Blood Glucose (FBG)Baseline, 36 Weeks
Change From Baseline in Body WeightBaseline, 24 Weeks
Change From Baseline in Body WeightBaseline, 36 Weeks
Population PK: Average Steady-State Plasma Concentration (Cav,ss) of LY3437943Predose: Week 0, 1, 4, 12, 24, 30; Postdose: Week 2, 8, 16, 20, 36
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04867785.

The type 2 diabetes phase 2 trial of retatrutide

Participants were randomised 2:2:2:1:1:1:1:2 to placebo, dulaglutide 1.5 mg or retatrutide maintenance doses from 0.5 mg to 12 mg weekly.[2]

At 36 weeks bodyweight fell by 3.19% on retatrutide 0.5 mg and by 16.94% on 12 mg, against 3.00% on placebo and 2.02% on dulaglutide.[2]

Mild-to-moderate gastrointestinal events were reported in 67 (35%) of 190 retatrutide participants and six (13%) of 45 on placebo.[2]

Body composition substudy

Total fat mass fell 4.9% on 0.5 mg, 15.2% on pooled 4 mg, 26.1% on pooled 8 mg and 23.2% on 12 mg, against 4.5% on placebo.[3]

The authors reported that lean mass loss, as a share of weight lost, was similar to other obesity treatments.[3]

Appetite and eating behaviour

Appetite scores and the Eating Inventory were analysed at 24 and 36 weeks in 275 adults with type 2 diabetes.[4]

Reductions in Perceived Hunger and Disinhibition, and increases in Dietary Restraint, correlated with weight loss at week 36 (r = 0.28, 0.36 and 0.31).[4]

Sources

  1. 1A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
  3. 3Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
  4. 4Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.Diabetes, obesity & metabolism · 2025PMID 40916752Accessed 2 Oct 2026

Found an error? Report a correction.